Data set related to the article: "Effects of Human LAV-BPIFB4 Gene Therapy on the Epigenetic Clock and Health of Aged Mice"

The homozygous genotype of the Longevity-Associated Variant (LAV) in Bactericidal/Permeability-Increasing Fold-Containing Family B member 4 (BPIFB4) is enriched in long-livingindividuals of three independent populations and its genetic transfer in C57BL/6J mice showed adelay in frailty progression and improvement of several biomarkers of aging and multiple aspects ofhealth. The C57BL/6J strain is a suitable model for studying therapies aimed at extending healthyaging and longevity due to its relatively short lifespan and the availability of aging biomarkers.Epigenetic clocks based on DNA methylation profiles are reliable molecular biomarkers of aging,while frailty measurement tools are used to evaluate overall health during aging. In this study, weshow that the systemic gene transfer of LAV-BPIFB4 in aged C57BL/6J mice was associated with asignificant reduction in the epigenetic clock-based biological age, as measured by a three CpG clockmethod. Furthermore, LAV-BPIFB4 gene transfer resulted in an improvement of the Vitality Scorewith a reduction in the Frailty Index. These findings further support the use of LAV-BPIFB4 genetherapy to induce beneficial effects on epigenetic mechanisms associated with aging and frailty inaged mice, with potential implications for future therapies to prevent frailty in humans.